Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

about

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.Molecular mechanism of the role of carbamyl erythropoietin in treating diabetic retinopathy rats.

P2860

Q52691073-7A5DD773-93F0-48C9-AF91-47BCD7C77AF5 Q55289961-3780AA14-3346-42BE-B572-1034343D8BD2

P2860

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

Item

http://www.wikidata.org/entity/Q36045779

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Biphasic insulin Aspart 30 vs. ...... ts; a cost-effectiveness study

@ast

Biphasic insulin Aspart 30 vs. ...... ts; a cost-effectiveness study

@en

type

Item

label

Biphasic insulin Aspart 30 vs. ...... ts; a cost-effectiveness study

@ast

Biphasic insulin Aspart 30 vs. ...... ts; a cost-effectiveness study

@en

prefLabel

Biphasic insulin Aspart 30 vs. ...... ts; a cost-effectiveness study

@ast

Biphasic insulin Aspart 30 vs. ...... ts; a cost-effectiveness study

@en

P1476

Biphasic insulin Aspart 30 vs. ...... ts; a cost-effectiveness study

@en

P2093

Abbas Kebriaeezadeh

http://www.w3.org/2001/XMLSchema#string

Alireza Esteghamati

http://www.w3.org/2001/XMLSchema#string

Amir Farshchi

http://www.w3.org/2001/XMLSchema#string

Marjan Rashed

http://www.w3.org/2001/XMLSchema#string

Maryam Oskuee

http://www.w3.org/2001/XMLSchema#string

Rokhsareh Aghili

http://www.w3.org/2001/XMLSchema#string

Sina Noshad

http://www.w3.org/2001/XMLSchema#string

P2860

Economic costs of diabetes in the U.S. in 2012

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

EuroQol--a new facility for the measurement of health-related quality of life

Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.

Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.

Insulin analogues and their potential in the management of diabetes mellitus.

Costs of diabetes. A methodological analysis of the literature.

Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with Basal insulin: findings from the multinational, non-interventional a1chieve study.

Insulin analogs with improved pharmacokinetic profiles.

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

P2888

s12902-016-0116-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12902-016-0116-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maryam Kia

P577

2016-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021314800

http://www.w3.org/2001/XMLSchema#string

P698

27278922

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4899904

http://www.w3.org/2001/XMLSchema#string

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

about

P2860

P2860

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932